Want to see NUTX full AI Analyst Report?
NUTX Stock Chart & Stats
$145.87
-$7.69(-5.01%)
At close: 4:00 PM EDT
$145.87
-$7.69(-5.01%)
Day’s Range― - ―
52-Week Range$77.21 - $204.00
Previous Close$145.87
Volume132.68K
Average Volume (3M)120.76K
Market Cap
$1.28B
Enterprise Value$1.45K
Total Cash (Recent Filing)$205.21M
Total Debt (Recent Filing)$347.34M
Price to Earnings (P/E)7.1
Beta2.42
Next Earnings
Nov 24, 2026EPS Estimate
5.89Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)26.23
Shares Outstanding6,847,973
10 Day Avg. Volume109,184
30 Day Avg. Volume120,759
Financial Highlights & Ratios
PEG Ratio1.68
Price to Book (P/B)3.18
Price to Sales (P/S)1.20
P/FCF Ratio4.26
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$266.67Price Target Upside82.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)26.16
Revenue Forecast (FY)$873.12M
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationImproved operating cash flow and cash conversion provide funding for hospital expansion, reduce dependence on external capital, and strengthen resilience. Cash of roughly $205–207 million alongside net long-term debt of $31.1 million supports financial flexibility.
Lower Arbitration CostsThe CMS IDR fee cut and HaloMD pay-on-collected agreement alter the company’s ongoing cost structure rather than providing only a one-time benefit. Sustained savings should support margins and improve the economics of dispute-resolution activity.
Hospital Volume And ExpansionHigher patient volumes, positive same-hospital growth, and a pipeline targeting three to five openings annually provide a durable route to capacity and revenue growth. Service-line expansion and population-health growth may also strengthen referrals and retention.
Bears Say
Weak Reported Revenue GrowthDespite higher visits, reported revenue remains pressured by normalization from prior IDR catch-up effects and elevated revenue per visit in the comparison period. Continued top-line weakness could limit operating leverage and make profitability less durable.
Receivables And Insurer RiskLarge receivables and slow insurer concessions create collection-timing and reimbursement uncertainty. Although the company reports strong IDR win and collection rates, delayed payments can constrain cash conversion and increase execution risk in a claims-driven model.
Historically Volatile Capital StructureCurrent leverage is healthier, yet the history of high debt and substantial equity volatility indicates that balance-sheet stability has not been proven across cycles. A weaker operating period could again reduce financial flexibility and amplify funding risk.
Clinigence Holdings News
NUTX FAQ
What was Clinigence Holdings Inc’s price range in the past 12 months?
Clinigence Holdings Inc lowest stock price was $77.21 and its highest was $204.00 in the past 12 months.
What is Clinigence Holdings Inc’s market cap?
Clinigence Holdings Inc’s market cap is $1.28B.
When is Clinigence Holdings Inc’s upcoming earnings report date?
Clinigence Holdings Inc’s upcoming earnings report date is Nov 24, 2026 which is in 99 days.
How were Clinigence Holdings Inc’s earnings last quarter?
Clinigence Holdings Inc released its earnings results on Aug 06, 2026. The company reported $9.38 earnings per share for the quarter, beating the consensus estimate of $4.954 by $4.426.
Is Clinigence Holdings Inc overvalued?
According to Wall Street analysts Clinigence Holdings Inc’s price is currently Undervalued.
Does Clinigence Holdings Inc pay dividends?
Clinigence Holdings Inc does not currently pay dividends.
What is Clinigence Holdings Inc’s EPS estimate?
Clinigence Holdings Inc’s EPS estimate is 5.89.
How many shares outstanding does Clinigence Holdings Inc have?
Clinigence Holdings Inc has 6,847,973 shares outstanding.
What happened to Clinigence Holdings Inc’s price movement after its last earnings report?
Clinigence Holdings Inc reported an EPS of $9.38 in its last earnings report, beating expectations of $4.954. Following the earnings report the stock price went up 6.674%.
Which hedge fund is a major shareholder of Clinigence Holdings Inc?
Currently, no hedge funds are holding shares in NUTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Clinigence Holdings Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$266.67 (82.81% Upside)
$266.67 (82.81% Upside)
Blogger Sentiment
Neutral
NUTX Sentiment 67%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.2%
Last 30 Days ▲ 4.7%
Last 30 Days ▲ 4.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
56.49%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
14.70%
Trailing 12-Months
Company Description
Clinigence Holdings Inc
Nutex Health, Inc. functions as a technology-powered enterprise delivering healthcare services, structured into two key segments: its Hospital division and its Population Health Management division. The Hospital division is tasked with developing and overseeing various healthcare models, encompassing micro-hospitals, specialized medical centers, and hospital outpatient facilities. This segment currently owns and operates 21 locations spanning eight different states. Meanwhile, the Population Health Management division establishes and manages provider networks, such as independent physician associations. Additionally, its management services organizations furnish administrative, operational, and support assistance to its associated hospitals and physician groups. A proprietary, cloud-based technology platform within this division is crucial; it aggregates patient and provider data from multiple information systems, settings, and sources to construct a holistic view, thereby enabling more effective care delivery. The company maintains its corporate headquarters in Houston, Texas.
NUTX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized multiple meaningful operational and financial positives: a large jump in net income driven by lower non-cash/one-time expenses (notably stock-based compensation swing), stronger adjusted EBITDA and operating income, cash-flow improvement, meaningful cost reductions tied to the HaloMD amendment and a CMS IDR fee cut, sustained patient-volume growth and an active de novo development pipeline. Offsetting these positives were declines in reported revenue year-over-year (largely explained by prior-period IDR catch-up effects), higher G&A as a percent of revenue, and slower-than-desired insurer behavior and contract progress. On balance, the scale and persistence of the liquidity, profitability, arbitration cost savings, and volume improvements outweigh the revenue comparability headwinds and insurer uncertainties.View all NUTX earnings summariesNUTX Stock 12 Month Forecast
Average Price Target
$266.67
▲(82.81% Upside)
Technical Analysis
AMN Healthcare Services
―
Pennant Group
―
InnovAge Holding
―
Agilon Health
―
Ardent Health Partners, Inc.
―
Ownership Overview
32.77% Insiders
6.90% Mutual Funds
10.23% Other Institutional Investors
35.83% Public Companies and
Individual Investors